Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Jascayd is a prescription phosphodiesterase 4 inhibitor containing nerandomilast. Current U.S. labeling includes treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults. Tablets contain 9 mg or 18 mg.
read more about jascayd ...Nerandomilast inhibits phosphodiesterase 4 with preferential activity against the PDE4B isoenzyme. PDE4B inhibition raises intracellular cyclic adenosine monophosphate and reduces expression of profibrotic growth factors and inflammatory cytokines associated with pulmonary fibrosis.
Jascayd is used in adults with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis. Current labeling lists no contraindications. Clinical trials included patients receiving background nintedanib or pirfenidone and patients receiving no background antifibrotic treatment.
The recommended dose is 18 mg by mouth twice daily about 12 hours apart with or without food. The dose can be reduced to 9 mg twice daily when 18 mg twice daily is not tolerated, except with concomitant moderate CYP3A inducers or pirfenidone. Strong CYP3A inhibitors require a 9 mg twice-daily dose.
The most common adverse reactions include diarrhea, upper respiratory tract infection, depression-related events, decreased weight, decreased appetite, nausea, fatigue, headache, vomiting, back pain, and dizziness. Strong CYP3A inducers are avoided. Diarrhea is the adverse reaction most frequently linked to treatment discontinuation in clinical trials.
Jascayd treats idiopathic pulmonary fibrosis and progressive pulmonary fibrosis in adults.
The recommended dose is 18 mg twice daily about 12 hours apart with or without food.
Yes. The dose can be reduced to 9 mg twice daily for intolerance under the conditions described in current labeling.
Diarrhea was the most common adverse reaction in the clinical trials described in current labeling.
FDA Approves Drug to Treat Chronic, Progressive Lung Disease. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-chronic-progressive-lung-disease. Date Accessed October 6, 2026.
FDA Approves Drug to Treat Idiopathic Pulmonary Fibrosis. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-idiopathic-pulmonary-fibrosis. Date Accessed October 6, 2026.
JASCAYD (Nerandomilast) Prescribing Information. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa1b14c6-957f-d326-5099-911bfe33e391. Date Accessed October 6, 2026.
Nerandomilast: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a625107.html. Date Accessed October 6, 2026.
Nerandomilast in Patients With Idiopathic Pulmonary Fibrosis. https://pubmed.ncbi.nlm.nih.gov/40387033/. Date Accessed October 6, 2026.